Results 181 to 190 of about 37,609 (272)

Pharmacology, Medicinal Chemistry, and Therapeutic Potential of Imidazoline Receptor Ligands

ChemMedChem, Volume 21, Issue 13, 14 July 2026.
Building on the excellent review article by Dardonville and Rozas (2004), this paper summarizes the most representative ligands of imidazoline receptors (IR; I1, I2, and I3) and updates their pharmacological profiles. Although not exhaustive, it provides a solid starting point for understanding the significance of I2 IRs as promising therapeutic ...
Maria‐Eleni Kouridaki, Mercè Pallàs, Carmen Escolano   +2 more
wiley   +1 more source

Animal models of Huntington's disease. Pros and cons. [PDF]

Brain Behav Immun Health
Stepanova P, Voutilainen MH, Eriksson O, Lindholm D.   +3 more
europepmc   +1 more source

Redefining the role of the transfusion medicine physician in the era of advanced cellular therapies

Transfusion, EarlyView.
Eric A. Gehrie, Kevin J. Land
wiley   +1 more source

Patient Perspectives on Psychiatric Polygenic Risk Scores in Reproductive Decision‐Making and Polygenic Embryo Screening

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, Volume 201, Issue 5, Page 338-348, July 2026.
ABSTRACT Polygenic risk scores (PRS) estimate individuals' genetic risk for developing multifactorial conditions. Recent genome‐wide association studies have enabled development of psychiatric PRS, which hold potential to streamline diagnosis and treatment of psychiatric conditions.
Lauren A. Ginn, Amanda R. Merner, Page M. Trotter, Kaitlynn P. Craig, Abigail C. Martinez, Ana Lucía Battaglino, Dorit Barlevy, Daphne M. Ayton, Takahiro Soda, Eric A. Storch, Gabriel Lázaro‐Muñoz, Stacey Pereira   +11 more
wiley   +1 more source

How Early Does Anosognosia Begin in Huntington's Disease? [PDF]

Mov Disord Clin Pract
Bagga K, Xu A, Hall A, Kaur J, Gilbert PE, Corey-Bloom J.   +5 more
europepmc   +1 more source

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) can be caused by autosomal‐dominant familial Alzheimer's disease (FAD) mutations in amyloid precursor protein (APP) or presenilin‐1 and 2, which form an enzyme substrate complex. KAT5 binds to the APP intracellular domain.
Greg A Cary, Jessica E. Young, Shannon E. Rose, Harald Frankowski, Heather Wilkins, Sai Sruthi Amirtha Ganesh, Julia Draper, Martin Darvas, Mark Bothwell, Suman Jayadev, Aquene N. Reid, Anna Greenwood, Allan I. Levey, Karina Leal, Gregory W. Carter, Jesse C. Wiley   +15 more
wiley   +1 more source

Clinical implications of malnutrition in Huntington's disease progression: evidence from a Chinese cohort and Mendelian randomization. [PDF]

Front Nutr
Xia JQ, Cheng YF, Zhang SR, Ma YZ, Fu JJ, Yang TM, Zhang LY, Burgunder JM, Shang HF.   +8 more
europepmc   +1 more source

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom—Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract The Dame Barbara Windsor Dementia Goals Programme was launched by the UK Government to accelerate the development and delivery of new treatments for dementia. We present the recommendations from the Scientific Advisory Board, to enable timely access to therapies for the wider population, reducing health system burden while improving patient ...
Ruth M. McKernan, James B. Rowe, Sally John, Eric Karran, Helene A. Fachim, Sara Imarisio, Raj Long, Charlotte Teunissen, Sarah P. Slight, Catherine Mummery, John Hardy   +10 more
wiley   +1 more source

Executive Impairment in Huntington's Disease: Insights From a Systematic Review of the Literature. [PDF]

Brain Behav
Migliore S, Marcaccio M, Di Pompeo I, Marano M, Curcio G.   +4 more
europepmc   +1 more source

Advances in the Core Role and Mechanisms of Mitochondrial Dysfunction in Alzheimer's Disease

Brain and Behavior, Volume 16, Issue 7, July 2026.
In Alzheimer's disease, Aβ and Tau trigger mitochondrial dysfunction, driving a pathological cascade that results in cognitive decline. Gut microbiota dysbiosis exacerbates this via the gut–brain axis, making mitochondria a key therapeutic target. ABSTRACT Introduction Alzheimer's disease (AD) is a complex neurodegenerative disorder whose pathogenesis ...
Tianyi Gu, Hangyan Guo, Zixin Guo, Shengyu Hua   +3 more
wiley   +1 more source